Adaptimmune Therapeutics PLC (ADAP)

0.6048 0.00 (0.00%) USD  |  NASDAQ  |  Dec 20, 16:00
0.5958 -0.01 (-1.49%) After-Hours: 20:00
More

Adaptimmune Therapeutics Max Drawdown (5Y): 96.45% for Nov. 30, 2024

Max Drawdown (5Y) Chart

View Max Drawdown (5Y) for ADAP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Max Drawdown (5Y) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Max Drawdown Definition

View Max Drawdown Definition
Start Trial

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
Biodexa Pharmaceuticals PLC 100.00%
NuCana PLC 99.46%
TC BioPharm (Holdings) PLC --
Verona Pharma PLC 89.71%
Autolus Therapeutics PLC 96.58%

Max Drawdown (5Y) Related Metrics

Alpha (5Y) -40.74
Beta (5Y) 2.179
Annualized Standard Deviation of Monthly Returns (5Y Lookback) 132.7%
Historical Sharpe Ratio (5Y) -0.0877
Historical Sortino (5Y) -0.2968
Monthly Value at Risk (VaR) 5% (5Y Lookback) 36.67%